Clinical Characterization of Pediatric Pulmonary Hypertension: Complex Presentation and Diagnosis
Objectives
To describe the clinical presentation of pediatric pulmonary arterial hypertension (PAH) and the intricacies of how to classify pediatric PAH according to the Venice classification.
Study design
Children (n = 63) seen at a national referral center for pediatric PAH underwent a diagnostic work-up for diagnosis of pulmonary hypertension (PH) and associated conditions and for assessment of the explanatory role of associated conditions for the PH. Subsequently, PH was classified.
Results
In 18 patients (29%), no associated conditions were identified; they were classified as having idiopathic PAH. In 45 patients (71%), ≥1 associated conditions were detected: congenital heart defects (CHD, n = 40), connective tissue disease (CTD, n = 2), disorders of respiratory system and/or hypoxemia (RSH, n = 17), and chronic thromboembolic disease (CTE, n = 1). Patients were classified according to the condition judged to be primarily explanatory for the PH. In 11 of 45 patients with associated conditions, the PH was not sufficiently explained by these conditions; these patients were classified as having idiopathic-like PAH. In 17 of 40 cases of CHD and 9 of 17 cases of RSH, these conditions were not sufficiently explanatory for the PH. Syndromal abnormalities were frequent (43%). Ultimately, classification revealed idiopathic (-like) PAH (n = 29; 46%), PAH-CHD (n = 23; 37%), PAH-CTD (n = 2; 3%), PH-RSH (n = 8; 12%), and CTE-PH (n = 1; 2%).
Conclusion
Pediatric PH frequently presents with associated conditions and syndromal abnormalities. However, detailed evaluation of this complex presentation reveals that associated conditions are not always explanatory for the PH.
ASD, Atrial septal defect, BMPR2, Bone morphogenetic protein receptor type 2, CHD, Congenital heart disease, CTD, Connective tissue disease, CTE, Chronic thromboembolic disease, PAH, Pulmonary arterial hypertension, PDA, Patent ductus arteriosus, PH, Pulmonary hypertension, RSH, Disorders of respiratory system and/or hypoxemia, TcSO2, Transcutaneous oxygen saturation, VSD, Ventricular septal defect
To access this article, please choose from the options below
R.B. has served on the advisory boards of Actelion Pharmaceuticals and GlaxoSmithKline, Gilead.
PII: S0022-3476(09)00157-7
doi:10.1016/j.jpeds.2009.02.036
© 2009 Mosby, Inc. All rights reserved.
